News|Articles|November 1, 2005

Pipeline Preview

Muraglitazar (Pargluva, Bristol-Myers Squibb, Merck) for the treatment of type 2 diabetes.

Approvable designations

Fast-track designations

Orphan drug designations

Non-approvable designations

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.


Latest CME